Orthofix Medical Inc. (NASDAQ:OFIX) Receives Consensus Rating of "Hold" from Brokerages

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $18.00.

Several equities research analysts have recently weighed in on OFIX shares. JMP Securities reaffirmed a "market perform" rating on shares of Orthofix Medical in a research report on Monday, April 22nd. StockNews.com raised shares of Orthofix Medical from a "sell" rating to a "hold" rating in a research report on Wednesday. Roth Capital raised shares of Orthofix Medical from a "neutral" rating to a "buy" rating in a research report on Wednesday. Finally, Roth Mkm raised shares of Orthofix Medical from a "neutral" rating to a "buy" rating and upped their price target for the stock from $15.00 to $20.00 in a research report on Wednesday.

Orthofix Medical Trading Down 2.8 %

OFIX stock traded down $0.41 during mid-day trading on Thursday, reaching $14.49. The company had a trading volume of 380,003 shares, compared to its average volume of 409,470. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.54 and a quick ratio of 1.20. The company has a market capitalization of $542.07 million, a PE ratio of -3.50 and a beta of 1.06. The firm has a 50 day moving average of $13.66 and a 200 day moving average of $13.03. Orthofix Medical has a 12 month low of $9.57 and a 12 month high of $21.60.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last issued its earnings results on Tuesday, March 5th. The medical device company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.01. The business had revenue of $200.42 million for the quarter. Orthofix Medical had a negative net margin of 20.28% and a negative return on equity of 10.63%. On average, equities analysts predict that Orthofix Medical will post -1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Orthofix Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Swiss National Bank lifted its position in Orthofix Medical by 1.3% during the third quarter. Swiss National Bank now owns 76,400 shares of the medical device company's stock valued at $983,000 after acquiring an additional 1,000 shares during the last quarter. Gladius Capital Management LP raised its holdings in shares of Orthofix Medical by 55.2% in the fourth quarter. Gladius Capital Management LP now owns 2,841 shares of the medical device company's stock worth $38,000 after buying an additional 1,010 shares during the last quarter. Gamco Investors INC. ET AL raised its holdings in shares of Orthofix Medical by 1.4% in the third quarter. Gamco Investors INC. ET AL now owns 91,400 shares of the medical device company's stock worth $1,175,000 after buying an additional 1,300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Orthofix Medical by 30.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company's stock worth $101,000 after buying an additional 1,752 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of Orthofix Medical by 34.7% in the first quarter. State Board of Administration of Florida Retirement System now owns 13,562 shares of the medical device company's stock worth $197,000 after buying an additional 3,490 shares during the last quarter. Hedge funds and other institutional investors own 89.76% of the company's stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.